Controlled-release products remain amongst the largest sectors for innovation, with worldwide revenues of US$29.5bn by 2017, as products mature and face patent expiration. Advances in nanobiotechnology, drug delivery vehicles, and formulation science have created unique opportunities for the development of a new generation of controlled delivery vehicles. With this in mind, SMi presents its 9th annual Controlled-Release conference to be held in London on Wednesday 28th & Thursday 29th of March 2012. This conference continues SMis previous highly successful Controlled-Release events and offers the opportunity to keep up-to-date with the latest regulations, challenges and solutions that you need to know about for successful and cost-effective drug delivery. New for 2012, the conference focuses more on developments in hard-to-formulate areas. Case studies by leading pharmaceutcal scientists include presentations on how chemistry and materials science are improving in-vivo stability, cellular and subcellular biorecognition and dissolution rate kinetics. Prolonging the functionality of active pharmaceutical ingredients to extend product life-cycles will feature clinical case studies from companies including GlaxoSmithKline, Lundbeck and Bristol-Myers Squibb.
